Song Yao1, Cecile A Laurent2, Janise M Roh2, Joan Lo2, Li Tang3, Theresa Hahn4, Christine B Ambrosone3, Lawrence H Kushi2, Marilyn L Kwan2. 1. Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. song.yao@roswellpark.org. 2. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. 3. Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. 4. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Abstract
PURPOSE: Osteoporosis and fragility fracture are major bone toxicities of aromatase inhibitors (AIs) for postmenopausal hormone receptor-positive breast cancer. Except for a few small studies on bone turnover markers and reduced bone mineral density after AI treatment, data on the associations of bone markers and risk of osteoporosis or fracture from prospective studies are lacking. METHODS: In a prospective study of 1709 women on AIs, two bone turnover markers, BALP and TRACP, and two bone regulatory markers, RANKL and OPG, were measured and examined in relation to risk of osteoporosis and fragility fractures during a median follow-up time of 6.1 years. RESULTS: Higher levels of BALP and TRACP were both associated with increased risk of osteoporosis and higher BALP/TRACP ratios were associated with lower risk of osteoporosis, but no associations were observed for fracture risk. Higher levels of OPG were associated with increased risk of fracture, whereas higher levels of RANKL were associated with lower risk. As a result, OPG/RANKL ratios were positively associated with fracture risk [hazard ratio (HR) = 2.49, 95% confidence interval (CI) 1.34-4.61]. After controlling for age and fracture history, the associations became non-significant but a suggestive trend remained (HR = 1.80, 95% CI 0.96-3.37). CONCLUSION: Our study provides suggestive evidence for the potential utility of OPG/RANKL ratios in predicting risk of fracture in women treated with AIs for breast cancer. Further validation may be warranted.
PURPOSE:Osteoporosis and fragility fracture are major bone toxicities of aromatase inhibitors (AIs) for postmenopausal hormone receptor-positive breast cancer. Except for a few small studies on bone turnover markers and reduced bone mineral density after AI treatment, data on the associations of bone markers and risk of osteoporosis or fracture from prospective studies are lacking. METHODS: In a prospective study of 1709 women on AIs, two bone turnover markers, BALP and TRACP, and two bone regulatory markers, RANKL and OPG, were measured and examined in relation to risk of osteoporosis and fragility fractures during a median follow-up time of 6.1 years. RESULTS: Higher levels of BALP and TRACP were both associated with increased risk of osteoporosis and higher BALP/TRACP ratios were associated with lower risk of osteoporosis, but no associations were observed for fracture risk. Higher levels of OPG were associated with increased risk of fracture, whereas higher levels of RANKL were associated with lower risk. As a result, OPG/RANKL ratios were positively associated with fracture risk [hazard ratio (HR) = 2.49, 95% confidence interval (CI) 1.34-4.61]. After controlling for age and fracture history, the associations became non-significant but a suggestive trend remained (HR = 1.80, 95% CI 0.96-3.37). CONCLUSION: Our study provides suggestive evidence for the potential utility of OPG/RANKL ratios in predicting risk of fracture in women treated with AIs for breast cancer. Further validation may be warranted.
Entities:
Keywords:
Bone markers; Breast cancer; Fracture; Osteoporosis
Authors: Edith A Perez; Robert G Josse; Kathleen I Pritchard; James N Ingle; Silvana Martino; Brian P Findlay; Tamara N Shenkier; Richard G Tozer; Michael J Palmer; Lois E Shepherd; Shifang Liu; Dongsheng Tu; Paul E Goss Journal: J Clin Oncol Date: 2006-07-05 Impact factor: 44.544
Authors: P Garnero; E Hausherr; M C Chapuy; C Marcelli; H Grandjean; C Muller; C Cormier; G Bréart; P J Meunier; P D Delmas Journal: J Bone Miner Res Date: 1996-10 Impact factor: 6.741
Authors: R C Coombes; L S Kilburn; C F Snowdon; R Paridaens; R E Coleman; S E Jones; J Jassem; C J H Van de Velde; T Delozier; I Alvarez; L Del Mastro; O Ortmann; K Diedrich; A S Coates; E Bajetta; S B Holmberg; D Dodwell; E Mickiewicz; J Andersen; P E Lønning; G Cocconi; J Forbes; M Castiglione; N Stuart; A Stewart; L J Fallowfield; G Bertelli; E Hall; R G Bogle; M Carpentieri; E Colajori; M Subar; E Ireland; J M Bliss Journal: Lancet Date: 2007-02-17 Impact factor: 79.321
Authors: Cornelis J H van de Velde; Daniel Rea; Caroline Seynaeve; Hein Putter; Annette Hasenburg; Jean-Michel Vannetzel; Robert Paridaens; Christos Markopoulos; Yasuo Hozumi; Elysee T M Hille; Dirk G Kieback; Lina Asmar; Jan Smeets; Johan W R Nortier; Peyman Hadji; John M S Bartlett; Stephen E Jones Journal: Lancet Date: 2011-01-22 Impact factor: 79.321
Authors: Song Yao; Yali Zhang; Li Tang; Janise M Roh; Cecile A Laurent; Chi-Chen Hong; Theresa Hahn; Joan C Lo; Christine B Ambrosone; Lawrence H Kushi; Marilyn L Kwan Journal: Breast Cancer Res Treat Date: 2016-12-03 Impact factor: 4.872
Authors: Olof Johnell; John A Kanis; Dennis M Black; Adam Balogh; Gyula Poor; Somnath Sarkar; Chunmei Zhou; Imre Pavo Journal: J Bone Miner Res Date: 2004-02-16 Impact factor: 6.741
Authors: Paul E Goss; James N Ingle; Kathleen I Pritchard; Matthew J Ellis; George W Sledge; G Thomas Budd; Manuela Rabaglio; Rafat H Ansari; David B Johnson; Richard Tozer; David P D'Souza; Haji Chalchal; Silvana Spadafora; Vered Stearns; Edith A Perez; Pedro E R Liedke; Istvan Lang; Catherine Elliott; Karen A Gelmon; Judy-Anne W Chapman; Lois E Shepherd Journal: J Clin Oncol Date: 2013-01-28 Impact factor: 44.544
Authors: M Rabaglio; Z Sun; K N Price; M Castiglione-Gertsch; H Hawle; B Thürlimann; H Mouridsen; M Campone; J F Forbes; R J Paridaens; M Colleoni; T Pienkowski; J-M Nogaret; I Láng; I Smith; R D Gelber; A Goldhirsch; A S Coates Journal: Ann Oncol Date: 2009-05-27 Impact factor: 32.976
Authors: Marilyn L Kwan; Joan C Lo; Li Tang; Cecile A Laurent; Janise M Roh; Malini Chandra; Theresa E Hahn; Chi-Chen Hong; Lara Sucheston-Campbell; Dawn L Hershman; Charles P Quesenberry; Christine B Ambrosone; Lawrence H Kushi; Song Yao Journal: PLoS One Date: 2014-10-29 Impact factor: 3.240